Continuous glucose monitors (CGM) and diabetes devices: global regulation and registration

For every regulator below we answer the three questions diabetes device teams ask first: what class is my product, how long will it take, and what will it cost. Every cost has two parts, the government fee and our flat annual service fee, and the current figures live in our pricing calculator.

What is a continuous glucose monitor (CGM)?

A continuous glucose monitor (CGM) is a wearable device that measures glucose in the interstitial fluid under the skin through a small sensor and reports readings continuously to a receiver, a smartphone app, or a connected insulin pump. Most systems are factory-calibrated and worn for 10 to 15 days, and one implantable sensor lasts several months. Diabetes care covers a wider family of devices around the CGM: insulin pumps and automated insulin delivery (AID) systems, sometimes called an artificial pancreas, plus the blood glucose meters and disposable test strips used for fingerstick checks.

These devices do not all sit under the same rules, which is what makes the category tricky. CGM sensors and insulin pumps are medical devices; blood glucose meters and test strips are in vitro diagnostics (IVDs) on a separate regulatory track; and the companion phone app and the AID control algorithm are themselves software as a medical device. Every jurisdiction then draws the lines differently: the same CGM can be a prescription Class II device in the United States, an over-the-counter product for people not on insulin, and an MDR Class IIb device in Europe whose companion test strips fall under a different regulation entirely. A structured classification analysis across your target markets is the first deliverable of any serious diabetes-device program, and our CGM market-access research report walks through the market-by-market picture.

FDA CGM regulation (United States)

FDA regulates CGMs and insulin pumps as devices, with dedicated special controls and interoperable-component categories, while blood glucose meters and test strips are cleared as in vitro diagnostics. Software documentation, cybersecurity evidence, and human-factors testing all sit inside a diabetes submission.

• Classification. Integrated continuous glucose monitors (iCGM) are Class II with special controls under 21 CFR 862.1355; the first was authorized through De Novo and later systems clear via 510(k). Insulin pumps are Class II, and FDA's interoperable stack lets an Alternate Controller Enabled (ACE) pump, an iCGM, and an interoperable automated glycemic controller combine into an automated insulin delivery system. Blood glucose meters and strips are Class II IVDs.
• Timeline. A 510(k) typically runs 3 to 9 months end to end including preparation and FDA interaction; a De Novo for a novel CGM or controller plans for 9 to 15 months. A Pre-Sub meeting adds a few weeks up front and routinely saves review cycles later.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses) plus US$11,423 per year in establishment registration; De Novo runs far higher. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Over-the-counter (OTC) CGMs

Since 2024 the FDA has cleared the first over-the-counter (OTC) continuous glucose monitors: sensors sold without a prescription to adults who do not use insulin, aimed at people managing type 2 diabetes without insulin, at prediabetes, and at general glucose awareness. An OTC CGM is still a Class II device with the same integrated-CGM special controls; what changes is the intended-use population, the labeling, and the human-factors evidence that a lay user can apply and read the sensor without a clinician, not the regulatory class. OTC status is also market-specific: in the EU the same sensor still needs full MDR conformity, and prescription and reimbursement rules differ by country.

Start from our United States market page for the full FDA pathway.

EU MDR and IVDR: CGM classification and CE marking

Europe splits the diabetes portfolio across two regulations. CGM sensors and insulin pumps are medical devices under the MDR, while blood glucose meters and test strips are in vitro diagnostics under the IVDR (Regulation 2017/746). A notified body sits inside both timelines, and IVDR capacity in particular is tight.

• Classification. Under the MDR, CGM sensors are active monitoring devices, typically Class IIb, and insulin pumps that deliver a medicinal product are also generally Class IIb. Under the IVDR, blood glucose meters and test strips for glucose self-testing are Class C under Rule 4(a) (the rule's Class B exception covers glucose detection in urine, not blood). Genuinely low-risk classes are the exception across the diabetes portfolio.
• Timeline. Plan 9 to 18 months with a notified body for a first MDR Class IIb certification, and a similar window for an IVDR Class C certification, driven by notified body capacity and the maturity of your technical documentation and clinical or performance evaluation.
• Cost. There is no central government fee; the money goes to the notified body, typically EUR 30,000 to 70,000 across a first Class IIa/IIb certification cycle plus annual surveillance, and to building MDR- and IVDR-grade documentation. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

Notified body strategy should shape your EU plan early; see the European Union market page for the MDR and IVDR routes.

CGM registration in Brazil and Latin America (ANVISA)

Brazil anchors any Latin American strategy. ANVISA regulates CGMs and insulin pumps as medical devices, classified under RDC 751/2022, and blood glucose meters and test strips as in vitro diagnostics under RDC 830/2023. Both the device and IVD routes require a local representative, and we act as Brazil Registration Holder without taking control of your registration; Mexico's COFEPRIS is the region's second gate.

• Classification. RDC 751 follows the IMDRF model: lower-risk accessories can use the streamlined notificação route, while CGMs, insulin pumps, and other higher-risk devices require full registro with deeper technical evidence. Glucose meters and strips classify separately as IVDs under RDC 830.
• Timeline. Notification is typically a matter of weeks; higher-risk registration plans for 6 to 12 months. In Mexico, COFEPRIS runs 6 to 12 months on the standard route, and faster where reliance on FDA or CE approvals applies.
• Cost. ANVISA government fees: R$1,406 to notify a Class I-II product; higher-risk family registration runs R$8,510 to R$19,856, plus a one-time international B-GMP certification of R$72,805 where required. COFEPRIS charges MX$16,499 for Class I, MX$24,198 for Class II, and MX$30,798 for Class III per registration. Our registration service starts at US$2,000 per year, and US$3,000 for high-risk classes.

Start with the Brazil market page; labeling, instructions for use, and submissions are prepared natively in Portuguese and Spanish.

CGM registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas diabetes-device teams enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a good FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN, including Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where reliance-friendly frameworks make each additional market incremental. Japan and Korea are the region's big mature prizes with their own systems and languages. China is the largest market but the hardest entry, with local type testing and the longest timelines, so treat it as its own program when the business case justifies it, not as a default stop.

• Classification. Singapore's HSA uses risk classes A through D, placing CGMs and insulin pumps in the upper classes (C or D), and ASEAN members track the same IMDRF-style model. Japan classifies against JMDN codes through PMDA; Korea's MFDS uses Classes I-IV; China's NMPA places CGMs and pumps in Class II or III. Blood glucose meters and strips are handled on each market's IVD track.
• Timeline. HSA abridged evaluation with a reference approval closes in 2 to 6 months; ASEAN registrations typically run 3 to 9 months per market on the back of the same dossier. Japan plans for 9 to 14 months via PMDA, Korea 6 to 12 months including KGMP, and China 12 to 24 months including type testing.
• Cost. Singapore's government fees are light: a SGD 560 application plus SGD 2,010 to 6,250 evaluation by class; Malaysia runs MYR 500 plus MYR 750 to 3,000, and Thailand THB 3,100 to 21,000 by class, with an added THB 53,000 expert review where required. Japan's PMDA review fees start around JPY 1 million, and China's NMPA fees for an imported Class II-III device run roughly RMB 210,000 to 310,000 before type testing. Our registration service starts at US$2,000 per year across Singapore and ASEAN; Japan, Korea, and China are quoted flat per market on the same model.

One well-built reference dossier does most of the region's work, and sequencing is the strategy. See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

CGM registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing diabetes-care regions, and its regulators are built around reliance: a strong FDA, CE, or other reference approval does most of the work when the dossier is assembled correctly. SFDA regulates CGMs and insulin pumps and requires a local Authorized Representative; the UAE's MOHAP is the second gate.

• Classification. SFDA classifies devices into risk classes A through D on the IMDRF model, mirroring your reference-market class in most cases, so a CGM or pump usually carries its FDA or MDR classification into the Gulf. The UAE and other MENA authorities lean on the reference approval's classification.
• Timeline. With a reference approval in hand, SFDA marketing authorization (MDMA) typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer.
• Cost. Government fees across the Gulf are modest, generally a few thousand US dollars' equivalent per authority, so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages; we cover the wider region under one program.

Evidence, quality system, and lifecycle

Diabetes devices carry some of the most concrete evidence expectations in the field. Accuracy studies against a laboratory reference, reported as MARD for CGMs, sit at the center of every submission, alongside ISO 13485 and FDA QMSR quality systems, IEC 60601 electrical safety and IEC 62304 software life-cycle files, and the interoperability evidence that lets iCGM, ACE pump, and controller components be cleared to work together. Because the AID control algorithm and companion apps keep evolving after clearance, plan the update path up front: FDA's Predetermined Change Control Plan (PCCP) framework lets anticipated algorithm and software modifications be pre-authorized in the original submission, so updates consistent with the plan ship without a new 510(k); in the EU, significant changes to a certified device go back through your notified body, so the change strategy belongs in the technical documentation from day one. Because these devices are worn by lay users and stream data to phones and pumps, human-factors testing under IEC 62366 and cybersecurity documentation that satisfies FDA, EU MDR, and IEC 81001-5-1 are not optional. After launch, accuracy monitoring, complaint handling, and vigilance keep every registration current; connected sensors have drawn regulator attention when they underperform, so post-market surveillance is a live obligation, not a formality.

One program, every major market

A global diabetes-device program is a sequencing problem: pick the anchor market, build the dossier once, and reuse the classification analysis, accuracy and clinical evidence, and QMS artifacts everywhere else, while keeping the device, IVD, and software pieces aligned. We run the full program from a single team, covering strategy, submissions, in-country representation, and post-market maintenance, with transparent government fees and timelines in our pricing calculator.